JFG
IBRX icon

Jefferies Financial Group’s ImmunityBio IBRX Stock Holding History

Jefferies Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
+300,000
New +$2.05M 0.02% 592
2024
Q3 		– Sell
-15,000
Closed -$94.8K – 1590
2024
Q2 		$94.8K Buy
+15,000
New +$98.9K ﹤0.01% 1285

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jefferies Financial Group's IBRX Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in ImmunityBio (IBRX) in Q1 2026: 300,000 shares worth $2.3M. The stake represents 0.02% of the portfolio and ranks #591 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in IBRX as recently as Q2 2024.

Jefferies Financial Group first reported a position in IBRX in Q1 2023 and has held it in 3 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Jefferies Financial Group held 300,000 shares of ImmunityBio worth $2.3M as of Q1 2026.
  • ImmunityBio was a new Jefferies Financial Group position in Q1 2026.
  • ImmunityBio made up 0.02% of Jefferies Financial Group's portfolio in Q1 2026, its #591 holding.
  • Jefferies Financial Group first reported a position in ImmunityBio in Q1 2023 and has held it in 3 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.